Jilin Jian Yisheng Pharmaceutical Co., Ltd. (SHE:002566)

SHE:002566 Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022
Cash & Equivalents	234.37	63.55	71.48	487.73	343.26	219.7
Short-Term Investments	-	-	-	-	-	30.08
Trading Asset Securities	400.57	507.57	459.67	102.98	59.84	70.16
Cash & Short-Term Investments	634.94	571.13	531.15	590.72	403.11	319.94
Cash Growth	9.74%	7.53%	-10.08%	46.54%	25.99%	11.48%
Accounts Receivable	207.25	214.89	199.03	198.53	264	254.84
Other Receivables	24.7	14.76	10.53	11.75	22.23	39.61
Receivables	231.94	230.96	209.56	210.28	286.23	294.45
Inventory	1,575	1,581	1,626	1,617	1,603	1,597
Other Current Assets	11.94	14.7	8.58	13.32	10.17	10.53
Total Current Assets	2,454	2,398	2,376	2,431	2,303	2,222
Property, Plant & Equipment	407.7	417.13	450.34	483.66	526.11	501.49
Long-Term Investments	-	15.6	15.23	-	-	-
Goodwill	1.91	1.91	1.91	1.91	1.91	1.91
Other Intangible Assets	108.13	108.66	111.35	114.18	117.03	119.96
Long-Term Deferred Tax Assets	16.39	15.85	13.15	12.62	14.2	15.2
Long-Term Deferred Charges	1.33	1.54	2.15	2.02	3.07	2.99
Other Long-Term Assets	16.7	1.13	0.76	1.27	1.68	1.04
Total Assets	3,006	2,960	2,971	3,047	2,967	2,864

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022
Accounts Payable	13.17	11.69	13	24.86	24.33	19.81
Accrued Expenses	8.67	22.41	22.26	32.51	30.68	48.11
Short-Term Debt	346.6	308.23	290.28	470.43	430.43	397.86
Current Portion of Long-Term Debt	2.68	0.3	0.42	-	-	2.55
Current Portion of Leases	-	2.4	2.98	2.34	3.29	3.31
Current Income Taxes Payable	11.9	0.14	0.01	2.78	0.64	5.55
Current Unearned Revenue	10.59	14.77	5.49	11.01	24.51	16.72
Other Current Liabilities	24.9	24.17	31.55	45.91	74.29	39.84
Total Current Liabilities	418.51	384.1	366	589.85	588.16	533.75
Long-Term Debt	129.7	129.7	149.7	-	-	-
Long-Term Leases	3.44	5.34	6.21	4.03	9.82	11.46
Long-Term Unearned Revenue	106.41	108.87	112.54	118.69	118.02	120.85
Long-Term Deferred Tax Liabilities	2.67	2.34	2.77	1.74	1.17	0.02
Total Liabilities	660.73	630.35	637.22	714.3	717.18	666.08

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022
Common Stock	330.95	330.95	330.95	330.95	330.95	330.95
Additional Paid-In Capital	834.69	834.69	834.69	834.69	834.69	834.69
Retained Earnings	1,082	1,066	1,070	1,068	989.34	916.17
Total Common Equity	2,248	2,232	2,236	2,233	2,155	2,082
Minority Interest	97.84	97.76	97.83	99.26	94.45	116.47
Shareholders' Equity	2,345	2,329	2,333	2,332	2,249	2,198
Total Liabilities & Equity	3,006	2,960	2,971	3,047	2,967	2,864

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022
Total Debt	482.42	445.97	449.59	476.8	443.55	415.18
Net Cash (Debt)	152.52	125.16	81.56	113.92	-40.44	-95.24
Net Cash Growth	66.78%	53.45%	-28.40%	-	-	-
Net Cash Per Share	0.46	0.38	0.25	0.34	-0.12	-0.29
Filing Date Shares Outstanding	330.95	330.95	330.95	330.95	330.95	330.95
Total Common Shares Outstanding	330.95	330.95	330.95	330.95	330.95	330.95
Working Capital	2,036	2,014	2,010	1,841	1,714	1,688
Book Value Per Share	6.79	6.74	6.76	6.75	6.51	6.29
Tangible Book Value	2,138	2,121	2,122	2,117	2,036	1,960
Tangible Book Value Per Share	6.46	6.41	6.41	6.40	6.15	5.92
Buildings	-	548.36	548.14	548.14	545.7	400.71
Machinery	-	352.2	353.49	359	357.13	321.57
Construction In Progress	-	-	-	-	1.98	119.32

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 4, 2026

Data Sources Report a data error